GILEAD SCIENCES, INC. Interest Expense Nonoperating
GILEAD SCIENCES, INC. (GILD) reported Interest Expense Nonoperating of $247.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- GILEAD SCIENCES, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $247.00M, a 2.76% decline year-over-year.
- GILEAD SCIENCES, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $240.00M, a 7.69% decline year-over-year.
- GILEAD SCIENCES, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $255.00M, a 2.41% increase year-over-year.
- GILEAD SCIENCES, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $256.00M, a 7.56% increase year-over-year.
- GILEAD SCIENCES, INC. interest expense nonoperating for fiscal 2025 was $1.02B, a 4.81% increase from fiscal 2024.
- GILEAD SCIENCES, INC. interest expense nonoperating for fiscal 2024 was $977.00M, a 3.50% increase from fiscal 2023.
- GILEAD SCIENCES, INC. interest expense nonoperating for fiscal 2023 was $944.00M, a 0.96% increase from fiscal 2022.
- GILEAD SCIENCES, INC. interest expense nonoperating for fiscal 2022 was $935.00M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $247.00M 10-Q · filed 2026-08-06 | $487.00M 10-Q · filed 2026-08-06 | $742.00M derived: sum of 3 quarters · filed 2026-08-06 | $998.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $240.00M 10-Q · filed 2026-05-07 | $495.00M derived: sum of 2 quarters · filed 2026-05-07 | $751.00M derived: sum of 3 quarters · filed 2026-05-07 | $1.00B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $255.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $511.00M derived: sum of 2 quarters · filed 2026-02-24 | $765.00M derived: sum of 3 quarters · filed 2026-08-06 | $1.02B 10-K · filed 2026-02-24 |
| 2025-09-30 | $256.00M 10-Q · filed 2025-11-07 | $510.00M derived: sum of 2 quarters · filed 2026-08-06 | $769.00M 10-Q · filed 2025-11-07 | $1.02B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $254.00M 10-Q · filed 2026-08-06 | $513.00M 10-Q · filed 2026-08-06 | $763.00M derived: sum of 3 quarters · filed 2026-08-06 | $1.00B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $260.00M 10-Q · filed 2026-05-07 | $509.00M derived: sum of 2 quarters · filed 2026-05-07 | $747.00M derived: sum of 3 quarters · filed 2026-05-07 | $984.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $249.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $487.00M derived: sum of 2 quarters · filed 2026-02-24 | $724.00M derived: sum of 3 quarters · filed 2026-02-24 | $977.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $238.00M 10-Q · filed 2025-11-07 | $475.00M derived: sum of 2 quarters · filed 2025-11-07 | $728.00M 10-Q · filed 2025-11-07 | $981.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $237.00M 10-Q · filed 2025-08-07 | $491.00M 10-Q · filed 2025-08-07 | $743.00M derived: sum of 3 quarters · filed 2026-02-24 | $975.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $254.00M 10-Q · filed 2025-05-07 | $506.00M derived: sum of 2 quarters · filed 2026-02-24 | $738.00M derived: sum of 3 quarters · filed 2026-02-24 | $968.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $252.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $484.00M derived: sum of 2 quarters · filed 2026-02-24 | $714.00M derived: sum of 3 quarters · filed 2026-02-24 | $944.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $232.00M 10-Q · filed 2024-11-12 | $462.00M derived: sum of 2 quarters · filed 2024-11-12 | $692.00M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $230.00M 10-Q · filed 2024-08-08 | $459.00M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $935.00M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |